Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.

Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork AC, Aubin HJ.

Eur J Public Health. 2009 Dec;19(6):650-4. doi: 10.1093/eurpub/ckp075. Epub 2009 Jun 2.

PMID:
19491286
2.

Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.

Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S.

Clin Drug Investig. 2009;29(10):655-65. doi: 10.2165/11317730-000000000-00000.

PMID:
19715382
4.

Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.

Lutz MA, Lovato P, Cuesta G.

Hosp Pract (1995). 2012 Feb;40(1):24-34. doi: 10.3810/hp.2012.02.945.

PMID:
22406880
5.

A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.

Lock K, Wilson K, Murphy D, Riesco JA.

Expert Opin Pharmacother. 2011 Dec;12(17):2613-26. doi: 10.1517/14656566.2011.628935. Epub 2011 Oct 21.

PMID:
22017336
6.

Cost-effectiveness of varenicline for smoking cessation.

Keiding H.

Expert Rev Pharmacoecon Outcomes Res. 2009 Jun;9(3):215-21. doi: 10.1586/erp.09.19.

PMID:
19527093
7.

Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.

Keating GM, Lyseng-Williamson KA.

Pharmacoeconomics. 2010;28(3):231-54. doi: 10.2165/11204380-000000000-00000. Review.

PMID:
20108995
8.

Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.

Lutz MA, Lovato P, Cuesta G.

Hosp Pract (1995). 2012 Feb;40(1):35-43. doi: 10.3810/hp.2012.02.946.

PMID:
22406881
9.

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.

Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T.

Curr Med Res Opin. 2010 Mar;26(3):549-60. doi: 10.1185/03007990903542666.

PMID:
20050814
10.

Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.

Hoogendoorn M, Welsing P, Rutten-van Mölken MP.

Curr Med Res Opin. 2008 Jan;24(1):51-61.

PMID:
18021492
11.

Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.

Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Sykara G, Kyriopoulos J.

Clin Ther. 2012 Aug;34(8):1803-14. doi: 10.1016/j.clinthera.2012.07.002. Epub 2012 Jul 20.

PMID:
22818870
12.

Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation.

Mahmoudi M, Coleman CI, Sobieraj DM.

Int J Clin Pract. 2012 Feb;66(2):171-82. doi: 10.1111/j.1742-1241.2011.02877.x. Review.

PMID:
22257042
13.

Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.

Vemer P, Rutten-van Mölken MP.

Value Health. 2010 Mar-Apr;13(2):230-41. doi: 10.1111/j.1524-4733.2009.00612.x. Epub 2009 Sep 25.

14.

Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation.

Taylor M, Leonardi-Bee J, Agboola S, McNeill A, Coleman T.

Addiction. 2011 Oct;106(10):1819-26. doi: 10.1111/j.1360-0443.2011.03493.x. Epub 2011 Jul 27.

PMID:
21561499
15.

Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims.

Zeng F, Chen CI, Mastey V, Zou KH, Harnett J, Patel BV.

Clin Ther. 2011 Feb;33(2):225-34. doi: 10.1016/j.clinthera.2011.02.013.

PMID:
21497706
16.

Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.

Higashi H, Barendregt JJ.

Addiction. 2012 Mar;107(3):658-70. doi: 10.1111/j.1360-0443.2011.03632.x. Epub 2011 Nov 1.

PMID:
21883602
17.

'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.

Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D.

Health Technol Assess. 2008 Feb;12(2):iii-iv, ix-xi, 1-135. Review.

18.

An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy.

Wilson K, Hettle R, Marbaix S, Diaz Cerezo S, Ines M, Santoni L, Annemans L, Prignot J, Lopez de Sa E.

Eur J Prev Cardiol. 2012 Oct;19(5):1173-83. doi: 10.1177/1741826711420345. Epub 2011 Aug 12.

PMID:
21840967
19.

Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.

Bolin K, Mörk AC, Willers S, Lindgren B.

Respir Med. 2008 May;102(5):699-710. doi: 10.1016/j.rmed.2007.12.018. Epub 2008 Mar 4.

20.

The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model.

Knight C, Howard P, Baker CL, Marton JP.

Value Health. 2010 Mar-Apr;13(2):209-14. doi: 10.1111/j.1524-4733.2009.00672.x. Epub 2009 Nov 13.

Supplemental Content

Support Center